{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T15:39:55Z","timestamp":1760888395315},"reference-count":18,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2009,10,1]],"date-time":"2009-10-01T00:00:00Z","timestamp":1254355200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2009,10]]},"DOI":"10.1016\/j.clinthera.2009.10.005","type":"journal-article","created":{"date-parts":[[2009,11,17]],"date-time":"2009-11-17T09:48:11Z","timestamp":1258451291000},"page":"2098-2106","source":"Crossref","is-referenced-by-count":6,"title":["Potential interactions between cilostazol and probucol: A two-part, single-dose, open-label study in healthy Korean male volunteers"],"prefix":"10.1016","volume":"31","clinical-trial-number":[{"clinical-trial-number":"nct00549978","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Kyu-pyo","family":"Kim","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bo-Hyung","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyoung Soo","family":"Lim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tae-Eun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sang-Goo","family":"Shin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"In-Jin","family":"Jang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyung-Sang","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2009.10.005_bib1","doi-asserted-by":"crossref","first-page":"10K","DOI":"10.1016\/j.amjcard.2007.06.003","article-title":"Pharmacologic approaches to restenosis prevention","volume":"100","author":"Douglas","year":"2007","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.clinthera.2009.10.005_bib2","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1345\/aph.19408","article-title":"Cilostazol: Treatment of intermittent claudication","volume":"35","author":"Reilly","year":"2001","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.clinthera.2009.10.005_bib3","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1191\/096032700678827717","article-title":"In vitro metabolism and interaction of cilostazol with human hepatic cytochrome P450 isoforms","volume":"19","author":"Abbas","year":"2000","journal-title":"Hum Exp Toxicol"},{"issue":"Suppl 2","key":"10.1016\/j.clinthera.2009.10.005_bib4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/00003088-199937002-00001","article-title":"Cilostazol pharmacokinetics after single and multiple oral doses in healthy males and patients with intermittent claudication resulting from peripheral arterial disease","volume":"37","author":"Bramer","year":"1999","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.clinthera.2009.10.005_bib5","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s11883-000-0094-0","article-title":"Probucol","volume":"2","author":"Pfuetze","year":"2000","journal-title":"Curr Atheroscler Rep"},{"key":"10.1016\/j.clinthera.2009.10.005_bib6","doi-asserted-by":"crossref","first-page":"323","DOI":"10.2165\/00129784-200202050-00005","article-title":"Prevention of restenosis with antioxidants: Mechanisms and implications","volume":"2","author":"Tardif","year":"2002","journal-title":"Am J Cardiovasc Drugs"},{"key":"10.1016\/j.clinthera.2009.10.005_bib7","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1056\/NEJM199708073370601","article-title":"Probucol and multivitamins in the prevention of restenosis after coronary angioplasty","volume":"337","author":"Tardif","year":"1997","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2009.10.005_bib8","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/S0002-9149(98)00323-3","article-title":"Effects of probucol and cilostazol alone and in combination on frequency of poststenting restenosis","volume":"82","author":"Sekiya","year":"1998","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.clinthera.2009.10.005_bib9","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.brainres.2007.04.051","article-title":"Beneficial synergistic effects of concurrent treatment with cilostazol and probucol against focal cerebral ischemic injury in rats","volume":"1157","author":"Park","year":"2007","journal-title":"Brain Res"},{"key":"10.1016\/j.clinthera.2009.10.005_bib11","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/BF00544015","article-title":"Effects of clofibrate, bezafibrate, fenofibrate and probucol on plasma lipolytic enzymes in normolipaemic subjects","volume":"25","author":"Heller","year":"1983","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2009.10.005_bib12","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.2337\/dc05-2415","article-title":"Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes: The Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in Non-insulin-dependent diabetes mellitus (ASPEN)","volume":"29","author":"Knopp","year":"2006","journal-title":"Diabetes Care"},{"key":"10.1016\/j.clinthera.2009.10.005_bib13","series-title":"Pharmacokinetics in Drug Development: Clinical Study Design and Analysis","first-page":"79","article-title":"Food effect studies","author":"Bekersky","year":"2004"},{"key":"10.1016\/j.clinthera.2009.10.005_bib14","series-title":"Bioequivalence and Statistics in Clinical Pharmacology","author":"Patterson","year":"2006"},{"issue":"Suppl 2","key":"10.1016\/j.clinthera.2009.10.005_bib15","doi-asserted-by":"crossref","first-page":"61","DOI":"10.2165\/00003088-199937002-00007","article-title":"Effects of CYP3A inhibition on the metabolism of cilostazol","volume":"37","author":"Suri","year":"1999","journal-title":"Clin Pharmacokinet"},{"issue":"Suppl 2","key":"10.1016\/j.clinthera.2009.10.005_bib16","doi-asserted-by":"crossref","first-page":"53","DOI":"10.2165\/00003088-199937002-00006","article-title":"Effect of omeprazole on the metabolism of cilostazol","volume":"37","author":"Suri","year":"1999","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.clinthera.2009.10.005_bib17","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1248\/bpb.25.1112","article-title":"Effect of probucol on cytochrome P450 activities in human liver microsomes","volume":"25","author":"Umehara","year":"2002","journal-title":"Biol Pharm Bull"},{"key":"10.1016\/j.clinthera.2009.10.005_bib18","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1067\/mcp.2000.109366","article-title":"In vivo drug-drug interaction studies\u2014a survey of all new molecular entities approved from 1987 to 1997","volume":"68","author":"Marroum","year":"2000","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.clinthera.2009.10.005_bib19","series-title":"Pharmacokinetics in Drug Development: Clinical Study Design and Analysis","first-page":"31","article-title":"Drug\u2014drug interactions","author":"Charnick","year":"2004"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291809003622?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291809003622?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,12,15]],"date-time":"2018-12-15T05:51:02Z","timestamp":1544853062000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291809003622"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,10]]},"references-count":18,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2009,10]]}},"alternative-id":["S0149291809003622"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2009.10.005","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2009,10]]}}}